Business Wire

Pharnext’s PXT3003 Featured at the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) 2017 Annual Meeting

Jaa

Regulatory News:

Pharnext SA (Paris:ALPHA) (FR00111911287 - ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced that data related to PXT3003, the Company’s lead PLEODRUG™, in development for the treatment of Charcot-Matrie-tooth type 1A (CMT1A) disease will be presented in a poster viewing session at the AANEM 2017 Annual Meeting, September 13-16, in Phoenix, Arizona, U.S.

Details are as follow:

Date & Time   Title

September
14 -15, 2017
All day

 

 

Poster #90: “A multicenter, double-blind, placebo-controlled, pivotal Phase III study
(PLEOCMT) of a fixed combination of baclofen, naltrexone and sorbitol (PXT3003), for the
treatment of CMT1A” S. Attarian et al.

The abstract is available online at : http://www.aanem.org/Meetings/Annual-Meeting/Abstracts

About PXT3003

PXT3003, Pharnext’s lead PLEODRUG™ in development for the treatment of Charcot-Marie-Tooth type 1A disease (CMT1A), is a novel, synergistic, low-dose combination of baclofen, naltrexone, and D-sorbitol formulated as an oral solution given twice-daily. PXT3003 has multiple main mechanisms of action: a synergistic inhibition of PMP22 gene overexpression associated with myelination improvement, direct nerve protection and additional positive effects on other cellular types: muscle cells, neuromuscular junctions and immune cells. PXT3003 obtained positive results in a Phase II clinical trial in 80 adult patients with CMT1A. In 2014, the EMA and FDA granted orphan drug designation to PXT3003 for the treatment of CMT1A in adults. An international pivotal Phase III trial (PLEO-CMT) in over 300 adult patients with CMT1A is now underway at 30 sites across Europe, the U.S. and Canada.

About Pharnext

Pharnext is an advanced clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The Company identifies and develops synergic combinations of repositioned drugs at new optimal lower doses. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property including several product or composition of matter patents already granted. The Company is supported by a world-class scientific team.

The company Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN code: FR00111911287).
For more information, visit www.pharnext.com

Contact information

Pharnext
Xavier Paoli, +33 (0)1 41 09 22 30
Chief Commercial Officer
contact@pharnext.com
or
Investor Relations (Europe)
MC Services AG
Anne Hennecke, +49 211 529252 22
anne.hennecke@mc-services.eu
or
Media Relations (Europe)
ALIZE RP
Caroline Carmagnol
Margaux Pronost
+33 (0)1 44 54 36 64
pharnext@alizerp.com
or
Pharnext
René Goedkoop, +33 (0)1 41 09 22 30
Chief Medical Officer
contact@pharnext.com
or
Investor Relations (U.S.)
Stern Investor Relations, Inc.
Matthew Shinseki, +1 212-362-1200
matthew@sternir.com
or
Media Relations (U.S.)
Russo Partners
Tony Russo
Scott Santiamo
tony.russo@russopartnersllc.com
scott.santiamo@russopartnersllc.com
+1 212-845-4251
+1 718-344-5843
or
Financial Communication (France)
New CAP
Emmanuel Huynh, +33 (0)1 44 71 20 40
pharnext@newcap.eu

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

World’s 1st End-to-End Digital TETRA DAS for Critical Communications and Public Safety Networks by Maven Wireless.25.9.2017 16:40Tiedote

Maven Wireless, the game changer in wireless coverage, announced the arrival of the world’s 1 st end-to-end digital TETRA DAS, (Distributed Antenna System) for in-building coverage at, Critical Communications MENA 2017 in Dubai. Operators of Critical Communications and Public Safety networks are moving toward combining effective voice communication capabilities with nationwide public safety LTE networks, enabling features such as video streaming, file sharing and real-­time analytics, without compromising security. As TETRA is still being deployed by operators across the world, the networks must support coexistence between TETRA and public safety LTE. Maven Wireless is now introducing the world’s 1st end-to-end digital TETRA DAS system for Critical Communications networks to the market. ‘’Maven DAS e

The Geneva Association: Life Insurers Should Prepare for Implications of Genetics in Highly Fragmented Regulatory Landscape25.9.2017 15:00Tiedote

The Geneva Association, the leading international think tank of the insurance industry, has released the research paper Genetics and Life Insurance: A view into the microscope of regulation, in which it reviews key aspects of the use of genetic information in life insurance. The use of genetic information for life, disability, critical illness and long-term care insurance is likely to increase in spite of a highly fragmented regulatory environment. The growing availability of genetic testing at ever lower prices is already giving insureds the option to purchase online “direct-to-consumer” tests. One of the questions raised is whether policyholders should be required to share their genetic information with life insurers. The paper focuses specifically on the regulatory implications of genetic testing. Ronald Klein, Director of The Geneva Association’s Global Ageing res

Saudi Arabia Marks 87th National Day With Series of Concerts, Plays and Entertainment Events25.9.2017 02:40Tiedote

Saudi National Day celebrations continue apace through the holiday weekend, with a series of spectacular entertainment events across the Kingdom highlighting the country’s achievements. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170924005034/en/ The 99-story Kingdom Centre in Riyadh is illuminated against the night sky on September 23 with the portrait of sprinter Kariman Abuljadayel, who was a member of the Saudi contingent to the Rio Olympics in 2016. The Kingdom is celebrating the 87th anniversary of its founding with a series of spectacular entertainment events across the Kingdom highlighting the country's achievements. CIC/General Entertainment Authority (Photo: AETOSWire) According to the General Entertainment Authority - the body responsible for expanding the entertainment sector under Vision 2030 - a total of 27

California Sports Surfaces Announces New Senior Leadership22.9.2017 23:21Tiedote

The California Sports Surfaces (CSS) brand, as part of ICP Construction (ICP), today announces the appointments of Steve Lock as global vice president; John Graham as leader, strategic accounts and global relationships; and Malcolm Parkes as managing director, Australia California Sports Surfaces. CSS is the leading supplier of such prestigious sports surfacing solutions as DecoTurf, Plexicushion Prestige, Rebound Ace, Premier Sports Coatings, Premier Court and Plexitrac. These world-renowned product lines supply the US Open, the Australian Open and other distinguished sporting events. Steve Lock has assumed the role of global vice president, responsible for managing the US and global sales and marketing teams for California Sport Surfaces. He was previously the leader for California Sports Surfaces in Australia and the Asia/Pacific region, and will be relocating to ICP global headquar

CORRECTING and REPLACING Smiths Detection Wins Biggest Ever Single Order for Next-Generation Hold Baggage Scanner for Frankfurt Airport22.9.2017 19:02Tiedote

Please replace the release with the following corrected version due to multiple revisions to the headline, subhead and body of the release. The corrected release reads: SMITHS DETECTION WINS BIGGEST EVER SINGLE ORDER FOR NEXT-GENERATION HOLD BAGGAGE SCANNER FOR FRANKFURT AIRPORT Advanced HI-SCAN 10080 XCT hold baggage scanners offer flexible, sophisticated detection capabilities Smiths Detection has won its largest single order ever for its advanced HI-SCAN 10080 XCT hold baggage scanners, with an associated eight-year service agreement. The contract covers 35 of our HI-SCAN 10080 XCT next-generation scanners to support the upgrade to the ECAC Standard 3 explosives detection systems. The solution will deliver increased security and operational efficiency, and can easily be upgraded to mee

California Sports Surfaces’ Rebound Ace Portable Court to be Used at Inaugural Laver Cup22.9.2017 17:37Tiedote

California Sports Surfaces (CSS), a brand under ICP Construction (ICP), is pleased to announce its innovative Rebound Ace Portable sport surfacing system is being used in the inaugural Laver Cup in Prague, Czech Republic, Sept. 22-24, 2017. CSS’s Rebound Ace system was selected to provide comfort, consistency and playability to the Laver Cup participants, who represent the best tennis players in the world. For this event, organizers worked with California Sports Surfaces to create a stunning black surface that would keep spectators focused on the game play. Rebound Ace Portable is an interlocking, temporary court system that provides premium cushion and comfort to maximize players’ performance. It has been chosen for use for several high-profile events, including the Fed Cup, Davis Cup, and the Singapore-based WTA Finals, for which it was specifically created. Laver Cup is modeled afte

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme